Prescription of Jingdan Yimin for treatment of metabolic syndrome.

Jin-Ying TIAN; Ying ZHOU; Ling CHEN; Xiu-Li LI; Xiao-Lin ZHANG; Jing HAN; Qian LIU; Ya-Nan YANG; Zi-Ming FENG; Pei-Cheng ZHANG; Fei YE

Return

Prescription of Jingdan Yimin for treatment of metabolic syndrome.

Author: Jin-Ying TIAN ¹ ; Ying ZHOU ¹ ; Ling CHEN ¹ ; Xiu-Li LI ² ; Xiao-Lin ZHANG ¹ ; Jing HAN ¹ ; Qian LIU ¹ ; Ya-Nan YANG ¹ ; Zi-Ming FENG ¹ ; Pei-Cheng ZHANG ¹ ; Fei YE ¹
Author Information

1. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing 100050, China.
2. Medical College of Chifeng University, Chifeng 024000, China.
Publication Type:Journal Article
Keywords: hypercholesterolemia; insulin resistance; protein tyrosine phosphatas 1B; studies of prescription; α-glucosidase
From: China Journal of Chinese Materia Medica 2016;41(2):272-278
CountryChina
Language:Chinese
Abstract: Based on the theory of traditional Chinese medicine, modern methods for drug investigation such as molecular targets in vitro and effects in vivo were used to study the prescription of Jingdan Yimin(JD), including selection of raw materials, composition, proportion, and effective dose of the compounds for treatment of metabolic syndrome. The IRF mice models, characterized by insulin resistance and hypercholesterolemia, were induced by high fat diet. The insulin sensitivity was estimated with insulin tolerance test(ITT) and glucose tolerance test(GTT); the levels of blood glucose and total cholesterol(TC), and the activities of α-glucosidase, protein tyrosine phosphatase 1B(PTP1B), and fructose phosphate amide transferase(GFAT)were measured with biochemical methods, respectively. The sample H13(h) extracted from Rhodiola crenulata, Y12(y) from Cordyceps militaris, and D(d) from Rheum palmatum were selected according to the inhibition activity on both PTP1B and α-glucosidase in vitro, regulation on hypercholesterolemia in IRF mice, and effects on GFAT activity, respectively; their synergistic effects on the treatment of metabolic syndrome were determined in IRF mice; composition proportion of h∶y∶d was measured in accordance with the results of L8(27) orthogonal experiments targeting on the inhibition of both PTP1B and α-glucosidase; finally, the effective dose was assessed based on the effects on IGT and hypercholesterolemia, respectively, in IRF mice. In conclusion, the prescription JD is composed by R. crenulata, C. militaris, and R. palmatum with the rate of 20∶1∶1, and its effective oral dose is 200 mg•kg⁻¹ for treatment of metabolic syndrome; its main mechanism is to inhibit the targets PTP1B and α-glucosidase. Monarch drug, R. crenulata, can clear away the lung-heat, tonify Qi, resolve stasis and nourish the heart. Adjuvant drug, C. militaris, can tonify the lung Qi and the kidney essence, strengthen waist and knee, accompanied with R. crenulata to enhance the function of invigorating lung and kidney. Assistant drug, rhubarb, can clear heat, detoxify, and remove blood stasis. These three herbs are compatible to show the effects of tonifying Qi, nourishing essence, clearing heat, reducing phlegm and resolving masses for the treatment of metabolic syndrome.